Use of historical control data for assessing treatment effects in clinical trials
Kert Viele(University of Kentucky), Laura Thompson(United States Food and Drug Administration), Scott Berry(Queen's University), Sandrine Micallef(Sanofi (France)), Billy Amzal(Serco (United Kingdom)), Stacy Lindborg(Celsion (United States)), Nelson Kinnersley(University of Rochester), Beat Neuenschwander(Novartis (Switzerland)), Nathan Enas(Eli Lilly (United States)), Joseph G. Ibrahim(University of North Carolina at Chapel Hill), Brian P. Hobbs(Tellabs (Canada)), Fang Chen(Sichuan Provincial Hospital of Traditional Chinese Medicine), Satrajit Roychoudhury(Novartis (United States))
Cited by 505
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818